Skip Prep of Vaginal Delivery to Prevent Puerperal / Perinatal Infection in Vaginal Delivery
Primary Purpose
Vaginal Delivery, Surgical Site Infection
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Povidone-Iodine
Chlorhexidine
Sponsored by
About this trial
This is an interventional prevention trial for Vaginal Delivery focused on measuring Chlorhexidine-alcohol, Povidone-iodine, Perineal infection, Surgical site infection
Eligibility Criteria
Inclusion Criteria:
- Women with singleton pregnancy
- Women who will undergo vaginal delivery after 37+0/7 weeks of gestation
Exclusion Criteria:
- Women who are allergy to chlorhexidine, alcohol, iodine, or shellfish
- Women with any infection at perineum (before vaginal delivery)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
chlorhexidine
Povidone-iodine
Arm Description
Pre-vaginal delivery skip prep using chlorhexidine-alcohol
Pre-vaginal delivery skip prep using Povidone-iodine
Outcomes
Primary Outcome Measures
Number of participant with episiotomy site infection
Superficial or deep infection of episiotomy site
Secondary Outcome Measures
Full Information
NCT ID
NCT05122169
First Posted
November 8, 2021
Last Updated
November 16, 2021
Sponsor
Seoul National University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT05122169
Brief Title
Skip Prep of Vaginal Delivery to Prevent Puerperal / Perinatal Infection in Vaginal Delivery
Official Title
Establishment of Clinical Practice Guideline to Prevent Puerperal / Perinatal Infection in Vaginal Delivery for Pregnant Women and Newborns
Study Type
Interventional
2. Study Status
Record Verification Date
November 2021
Overall Recruitment Status
Not yet recruiting
Study Start Date
December 2021 (Anticipated)
Primary Completion Date
December 31, 2025 (Anticipated)
Study Completion Date
May 31, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seoul National University Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This is a multi-center, randomized, controlled trial study to find whether use of chlorhexidine-alcohol or povidone-iodine for pre-vaginal delivery skin prep is superior to reduce postpartum infection in pregnant women with vaginal delivery. The primary outcome is the episiotomy site infection.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Vaginal Delivery, Surgical Site Infection
Keywords
Chlorhexidine-alcohol, Povidone-iodine, Perineal infection, Surgical site infection
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
4140 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
chlorhexidine
Arm Type
Experimental
Arm Description
Pre-vaginal delivery skip prep using chlorhexidine-alcohol
Arm Title
Povidone-iodine
Arm Type
Active Comparator
Arm Description
Pre-vaginal delivery skip prep using Povidone-iodine
Intervention Type
Drug
Intervention Name(s)
Povidone-Iodine
Other Intervention Name(s)
Povidone-iodine 10%
Intervention Description
Skin preparation with povidone-iodine pre-vaginal delivery skin preparation.
Intervention Type
Drug
Intervention Name(s)
Chlorhexidine
Other Intervention Name(s)
Hexitanol 2% Soln., Chlorhexidine Gluconate Solution
Intervention Description
Skin preparation with chlorhexidine-alcohol pre-vaginal delivery skin preparation.
Primary Outcome Measure Information:
Title
Number of participant with episiotomy site infection
Description
Superficial or deep infection of episiotomy site
Time Frame
21 days
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
19 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Women with singleton pregnancy
Women who will undergo vaginal delivery after 37+0/7 weeks of gestation
Exclusion Criteria:
Women who are allergy to chlorhexidine, alcohol, iodine, or shellfish
Women with any infection at perineum (before vaginal delivery)
12. IPD Sharing Statement
Learn more about this trial
Skip Prep of Vaginal Delivery to Prevent Puerperal / Perinatal Infection in Vaginal Delivery
We'll reach out to this number within 24 hrs